CARDIFF ONCOLOGY INC (CRDF) Stock News

USA - NASDAQ:CRDF - US14147L1089 - Common Stock

2.13 USD

-0.02 (-0.93%)

Last: 11/14/2025, 8:00:00 PM

2.13 USD

0 (0%)

After Hours: 11/14/2025, 8:00:00 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

CRDF Latest News, Press Relases and Analysis

All

Press Releases

10 days ago - By: Cardiff Oncology, Inc.

Cardiff Oncology Reports Third Quarter 2025 Results and Provides Business Update

10 days ago - By: Cardiff Oncology, Inc.

Cardiff Oncology Reports Third Quarter 2025 Results and Provides Business Update

12 days ago - By: Cardiff Oncology, Inc.

Cardiff Oncology to Participate in Two Upcoming Investor Conferences

a month ago - By: Cardiff Oncology, Inc.

Cardiff Oncology to Participate in Two Upcoming Investor Conferences

3 months ago - By: Cardiff Oncology, Inc.

Cardiff Oncology to Participate in Three Upcoming Investor Conferences

3 months ago - By: Benzinga

A Glimpse Into The Expert Outlook On Cardiff Oncology Through 4 Analysts

4 months ago - By: The Motley Fool

Cardiff Oncology (CRDF) Q2 Loss Down 19%

3 months ago - By: Benzinga - Mentions: AMD CAT IT FOUR ...

AMD To Rally More Than 20%? Here Are 10 Top Analyst Forecasts For Wednesday

4 months ago - By: Cardiff Oncology, Inc.

Cardiff Oncology Announces Positive Data from Ongoing Randomized Phase 2 First-line RAS-mutated mCRC Clinical Trial (CRDF-004)

4 months ago - By: Cardiff Oncology, Inc.

Cardiff Oncology Reports Second Quarter 2025 Results and Provides Business Update

4 months ago - By: FN Media Group LLC - Mentions: ONCY ONC.CA MBIO VSTM ...

Global Oncology Breakthroughs Being Fueled by Advancements in Clinical Trials and New Therapies

5 months ago - By: Yahoo Finance - Mentions: VZ

Cardiff Oncology to share CRDF-004 trial data on July 29

5 months ago - By: Cardiff Oncology, Inc.

Cardiff Oncology Appoints Dr. Roger Sidhu as Chief Medical Officer and Announces Timing for the Next Update from the CRDF-004 Trial in First-Line RAS-mutated mCRC

6 months ago - By: Cardiff Oncology, Inc.

Cardiff Oncology Announces Positive Data from Investigator-Initiated Trial of Onvansertib in Combination with Paclitaxel in Metastatic Triple-Negative Breast Cancer Presented at ASCO 2025

6 months ago - By: Zacks Investment Research

Cardiff Oncology (CRDF) Upgraded to Buy: Here's What You Should Know

6 months ago - By: Zacks Investment Research - Mentions: IMTX

Cardiff Oncology (CRDF) Reports Q1 Loss, Lags Revenue Estimates

7 months ago - By: Zacks Investment Research - Mentions: ADCT

ADC Therapeutics SA (ADCT) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

7 months ago - By: Zacks Investment Research

Cardiff Oncology (CRDF) Expected to Beat Earnings Estimates: Should You Buy?

7 months ago - By: Cardiff Oncology, Inc.

Cardiff Oncology Announces a Second Patent for the Treatment of mCRC for Bev-Naïve Patients

7 months ago - By: Cardiff Oncology, Inc.

Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

7 months ago - By: Cardiff Oncology, Inc.

Cardiff Oncology Announces Completion of Enrollment in Phase 2 CRDF-004 Trial Evaluating Onvansertib for the Treatment of First-line RAS-mutated Metastatic Colorectal Cancer